Arvin Capital Management LP Acquires Shares of 31,170 Danaher Co. (NYSE:DHR)

Arvin Capital Management LP purchased a new stake in Danaher Co. (NYSE:DHR) during the 3rd quarter, Holdings Channel.com reports. The institutional investor purchased 31,170 shares of the conglomerate’s stock, valued at approximately $8,666,000. Danaher comprises approximately 2.8% of Arvin Capital Management LP’s portfolio, making the stock its 14th biggest position.

Other hedge funds and other institutional investors have also bought and sold shares of the company. CarsonAllaria Wealth Management Ltd. bought a new position in shares of Danaher in the second quarter worth about $25,000. nVerses Capital LLC bought a new stake in Danaher during the 2nd quarter worth $25,000. Teachers Insurance & Annuity Association of America acquired a new position in Danaher in the 3rd quarter worth about $39,000. MidAtlantic Capital Management Inc. bought a new position in Danaher in the third quarter valued at about $40,000. Finally, FSA Wealth Management LLC bought a new stake in shares of Danaher during the third quarter worth about $50,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. TD Cowen raised their price objective on shares of Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a report on Wednesday, October 23rd. Stephens reiterated an “overweight” rating and set a $315.00 price target on shares of Danaher in a report on Wednesday, October 23rd. Evercore ISI increased their price objective on Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Royal Bank of Canada cut their price objective on Danaher from $333.00 to $311.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 23rd. Finally, Robert W. Baird dropped their target price on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 23rd. Five investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $287.16.

Danaher Trading Up 0.4 %

Shares of DHR opened at $239.69 on Monday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. Danaher Co. has a 1-year low of $215.68 and a 1-year high of $281.70. The company has a market capitalization of $173.12 billion, a P/E ratio of 45.74, a P/E/G ratio of 4.41 and a beta of 0.85. The firm’s 50 day simple moving average is $254.59 and its 200 day simple moving average is $259.41.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. The business had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The company’s revenue for the quarter was up 3.1% on a year-over-year basis. During the same quarter last year, the business posted $2.02 earnings per share. Sell-side analysts forecast that Danaher Co. will post 7.5 earnings per share for the current fiscal year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, October 25th. Shareholders of record on Friday, September 27th were paid a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a dividend yield of 0.45%. The ex-dividend date of this dividend was Friday, September 27th. Danaher’s dividend payout ratio (DPR) is presently 20.61%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.